Anti-Dengue-Virus-Antikörper, Polypeptide mit Abweichenden Fc-Regionen und Verfahren zur Verwendung
Anmelder: Chugai Seiyaku Kabushiki Kaisha, Agency for Science, Technology and Research 🇯🇵
Details
- Veröffentlichungs-Nr.
- EP4744728
- Anmeldetag
- 15. September 2017
- Veröffentlichung
- 20. Mai 2026
- Rechtsraum
- EP
- IPC
- A61P31/12(GLIKNIK INC et al.)
Abstract
The disclosure provides anti-DENV antibodies and methods of making and using the same. Nucleic acids encoding anti- DENV antibodies and host cells comprising the nucleic acids are also provided. The anti-DENV antibodies have uses that include treating DENV infection. The disclosure also provided polypeptides containing a variant Fc region and methods of making the same. Nucleic acids encoding polypeptides and host cells comprising the nucleic acids are also provided. The polypeptides have uses that include treating a viral infection. Also claimed is a polypeptide comprising a Fc variant comprising at least one amino acid alteration in a parent Fc region, wherein the variant Fc region has a substantially decreased FcYR-binding activity and does not have a substantially decreased C1 q-binding activity when compared to the parent Fc region.
Anmelder
- Firmen
- Chugai Seiyaku Kabushiki Kaisha
Agency for Science, Technology and Research - Land
- 🇯🇵 Japan
Chugai Pharmaceutical Co., Ltd. ist ein japanisches Pharmaunternehmen mit Sitz in Tokio, das insbesondere Biopharmazeutika entwickelt und mehrheitlich zur Roche-Gruppe gehört.
398 Patente in unserer Datenbank
Staatliche Forschungsorganisation Singapurs (bekannt als A*STAR), zuständig für angewandte Forschung in Biomedizin, Physik und Ingenieurwissenschaften. Fördert Technologietransfer zwischen Wissenschaft und Industrie.
2.211 Patente in unserer Datenbank